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Understanding the mechanism by which ligands
affect receptor conformational equilibria is key in
accelerating membrane protein structural biology.
In the case of G protein-coupled receptors (GPCRs),
we currently pursue a brute-force approach for iden-
tifying ligands that stabilize receptors and facilitate
crystallogenesis. The nociceptin/orphanin FQ pep-
tide receptor (NOP) is a member of the opioid recep-
tor subfamily of GPCRs for which many structurally
diverse ligands are available for screening. We
observed that antagonist potency is correlated with
a ligand’s ability to induce receptor stability (Tm)
and crystallogenesis. Using this screening strategy,
we solved two structures of NOP in complex with
top candidate ligands SB-612111 and C-35. Docking
studies indicate that while potent, stabilizing antago-
nists strongly favor a single binding orientation, less
potent ligands can adopt multiple binding modes,
contributing to their low Tm values. These results
suggest a mechanism for ligand-aided crystallogen-
esis whereby potent antagonists stabilize a single
ligand-receptor conformational pair.
INTRODUCTION
G protein-coupled receptors (GPCRs) are intrinsically dynamic
cell-surface receptors that play many key roles in human physi-
ology and pathology, mediating the action of more than 30% of
clinically marketed drugs (Rask-Andersen et al., 2014).
Structural studies that inform our understanding of GPCR-
drug interactions are currently impeded by our lack of under-
standing surrounding receptor stabilization and its connection
to crystallogenesis.
Virtually all of the 31 unique GPCR structures available include
ligands that aid in receptor crystallogenesis, with ligand proper-Structure 23, 2291–22ties such as affinity (pKi), molecular weight (MW), and lipophilicity
(LogP or LogD) affecting the outcome of crystallization trials
(Zhang et al., 2015). In a recent survey of ligands from GPCR
co-crystal structures, 77% of ligands were found to possess af-
finities in the single-digit nanomolar range, 96% of ligands had
octanol-water partition coefficients (LogPs) below 5, and 76%
had MWs between 200 and 500 Da (Zhang et al., 2015). As
GPCRs are pervasive drug targets, it is not surprising that
many ligands that have been developed to target these recep-
tors fall within the well-known Lipinski ‘‘rule of five’’ criteria for
drug-like compounds (MW%500 Da, LogP%5) (Lipinski, 2004).
The ability of a ligand to increase a receptor’s stability, or
melting temperature (Tm), remains the single most predictive
metric for identifying promising candidate ligands for crystalliza-
tion trials, with 92% of crystallized ligand-receptor pairs pos-
sessing a Tm above 55
C (Alexandrov et al., 2008; Zhang et al.,
2015). Yet the mechanism by which select ligands stabilize
the receptor and facilitate GPCR crystallogenesis is not well
understood.
To examine the relationship between ligand-induced GPCR
stabilization and crystallogenesis, a receptor with an array of
structurally diverse, high-affinity ligands such as the nocicep-
tin/orphanin FQ (N/OFQ) peptide receptor (NOP) is ideal. NOP
is a member of the opioid receptor subfamily of GPCRs that
has emerged as a key drug target due to its developing role in
pain transmission, drug addiction, and anxiety, as well as loco-
motor and mood disorders (Lambert, 2008). Small-molecule an-
tagonists targeting NOP are under intense investigation for their
use as antidepressants (Gavioli and Calo, 2013), while NOP ag-
onists have shown promise as powerful analgesics that lack
abuse liability (Lin and Ko, 2013). The crystal structure of human
NOP in complex with the potent antagonist Banyu Compound-
24 (C-24) was recently solved to a resolution of 3.0 A˚, revealing
the first atomic details of the receptor aswell as specific contacts
made by C-24 within the orthosteric binding site (Thompson
et al., 2012).
Correlating Tm with a ligand’s biochemical and functional
propertiesmay help to explain themechanismbehind successful
crystallogenesis and expedite selection of the most favorable li-
gands for structural studies.99, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2291
Figure 1. Distribution of NOP Ligand Metrics in the Context of Receptor Stabilization
Ligand-induced N/OFQ peptide receptor (NOP) stability (melting temperature, Tm in
C) plotted against four ligand properties: (A) molecular weight (Da), (B)
calculated lipophilicity (LogD), (C) affinity (pKi), and (D) antagonist potency (pKB). No correlation is observed between receptor Tm and ligand size or lipophilicity,
whereas high (nanomolar range) ligand affinity is necessary, but not sufficient, to induce receptor stabilization. BRET functional data indicate a positive correlation
between antagonist potency and ligand-induced thermal stability (linear regression, r2 = 0.97, p < 0.001 with CL95% shown). Tm of the ligand-free receptor is
indicated as a dotted line at 48C. Antagonists are shown as red circles, agonists as green squares, and partial agonists as blue triangles. Empty red circles
indicate antagonists for which co-crystal structures could be obtained. Explicit values for all metrics are shown in Table S1 and primary BRET data are given in
Figure S2.RESULTS AND DISCUSSION
Distribution of Ligand Properties
Since its discovery in 1994, drug-discovery efforts targeting NOP
have produced a variety of agonists and antagonists in the form
of both small molecules and peptides (Mollereau et al., 1994;
Mustazza and Bastanzio, 2011). Fortuitously, many of these
structurally diverse ligands have high affinities, with dozens of li-
gands possessing Ki values in the low- to sub-nanomolar range.
Using the establishedCPM thermal stability assay (Alexandrov
et al., 2008), we measured the melting temperatures of 19 NOP-
ligand pairs and evaluated these results with respect to the li-
gand’s MW, calculated LogD, and pKi. As shown in Figure 1A,
we observed no correlation between MW and ligand-induced
thermal stability of NOP. Likewise, lipophilicity, given as the
pH- and pKa-dependent calculated octanol-water partition coef-
ficient LogD, also did not correlate with receptor stability (Fig-
ure 1B). Finally, although single-digit nanomolar affinities were
necessary for high thermal stabilities, high binding affinities alone2292 Structure 23, 2291–2299, December 1, 2015 ª2015 Elsevier Ltdwere not sufficient for inducing receptor stabilization, with some
high-affinity ligands such as UFP-101 (pKi > 10) conferring
limited receptor stability (Figure 1C) (Malfacini et al., 2015;
McDonald et al., 2003). These results suggest that although
many NOP ligands were developed with exceptional drug-like
characteristics, their use in structural studies may be limited by
their poor Tm values.
Focusing on the six highest-affinity NOP antagonists, we used
bioluminescent resonance energy transfer (BRET) to measure
the ability of NOP antagonists to inhibit agonist-induced recep-
tor/G-protein interactions (Figures 1D and S2). Rankings of
BRET-derived antagonist potencies agreed with those obtained
from different functional assays investigating recombinant hu-
man (calcium mobilization studies in cells expressing chimeric
G proteins) and native animal (in electrically stimulated mouse
vas deferens) NOP receptors (Fischetti et al., 2009; Goto et al.,
2006; McDonald et al., 2002; Spagnolo et al., 2007; Trapella
et al., 2006, 2009). Comparing these values with NOP-ligand
complex thermal stability results, we observed that antagonistAll rights reserved
Table 1. Summary of Data Collection and Refinement Statistics
Parameters NOP-C-35 NOP-SB-612111
Data Collection (APS GM/CA-CAT Beamline 23ID-B/D)
Resolution (A˚)a 30–3.0
(3.1–3.0)
30–3.0
(3.1–3.0)
No. of crystals 22 19
Cell dimensions
a, b, c (A˚) 42.1, 171.7,
66.5
42.3, 168.9,
65.5
a, b, g () 90.0, 103.3,
90.0
90.0, 103.5, 90.0
Space group P21 P21
Average redundancy 3.3 (3.0) 3.4 (3.3)
Completeness (%) 90.8 (90.6) 93.2 (91.8)
Mean I/sI 7.77 (1.18) 7.27 (1.19)
Rmerge (%)
b 19.2 (NA) 19.1 (NA)
Rmeas (%)
c 21.4 (NA) 22.2 (NA)
Rpim (%)
d 11.3 (85.9) 11.9 (83.7)
Unique reflections 16,902 16,552
Refinement
Resolution range of data
used (A˚)
29.63–3.00 29.85–3.00
Reflections used 16,668 16,523
R factore 23.5 24.0
Free R factorf 27.5 27.9
No. of protein molecules
in the asymmetric
unit
2 2
Total no. of non-hydrogen
atoms
A B A B
Receptor 2,139 2,094 2,142 2,175
BRIL NA 719 NA 710
Ligand 32 32 28 28
Lipids 23 23 60 29
Average B factors A B A B
Receptor 83.6 82.1 65.1 63.5
BRIL NA 108.1 NA 89.4
Ligand 84.2 94.9 63.4 72.9
Lipids 90.0 84.2 63.9 58.6
Overall Wilson B
value (A˚2)
85.9 64.5
RMSD from standard
values
Bonds (A˚) 0.004 0.004
Angles () 0.75 0.77
Ramachandran
plotg
Residues in favored
regions (%)
97.2 96.8
Residues in allowed
regions (%)
2.8 3.2
Table 1. Continued
Parameters NOP-C-35 NOP-SB-612111
Residues in disallowed
regions (%)
0.0 0.0
Ligand electron densities are shown in detail in Figure S1. NA, data not
available.
aValues in parentheses are for the highest-resolution shell.
bMerging R factor: Rmerge =
P
h
P
j
hIih  Ih;j
=Ph
P
j Ih;j ; where Ih is the
mean intensity of symmetry-equivalent reflections.
cRedundancy-independent merging R factor: Rmeas =
P
h
ﬃﬃﬃﬃﬃﬃﬃﬃ
nh
nh1
q
P
j
hIih  Ih;j
=Ph
P
j Ih;j ; where nh is the redundancy of structure factor
h, allowing individual reflections be weighted according to their redun-
dancy (Weiss, 2001).
dPrecision-indicating merging R factor: Rpim =
P
h
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1=nh  1
p
P
j
hIih  Ih;j
=Ph
P
j Ih;j describing the precision of the averaged mea-
surement (Weiss, 2001).
eR factor=
PjFobs  Fcalcj=
P
Fobs ; where Fobs and Fcalc are the
observed and calculated structure factor amplitudes, respectively.
fFreeR factor value was calculated as theR factor for an unrefined subset
of reflection data (5% of reflections).
gRamachandran plot was calculated usingMolProbity (Chen et al., 2010).
Structure 23, 2291–22potency (pKB) and receptor thermal stability (Tm) are positively
correlated (linear regression r2 = 0.97, p < 0.001).
NOP in Complex with Antagonists SB-612111 and C-35
Having identified SB-612111 and Compound-35 (C-35) as the
two next most promising ligands for crystallogenesis, we used
lipidic cubic phase (LCP) crystallization to determine the struc-
ture of NOP in complex with these two antagonists, both to a res-
olution of 3.0 A˚ (for crystallographic statistics, see Table 1).
The piperidine-based antagonist SB-612111 is a popular tool
compound in in vitro and in vivo studies of NOP due to its high
affinity (pKi = 9.18) and selectivity (>1,000-fold) toward NOP
over classical opioid receptors (Spagnolo et al., 2007). The
diverse therapeutic potential of SB-612111 has been demon-
strated through multiple animal studies in which it has been
shown to act as an antidepressant (Rizzi et al., 2007), reduce
morphine tolerance (Zaratin et al., 2004), promote antiparkinso-
nian effects (Marti et al., 2013), and ameliorate colitis in animal
models of inflammatory bowel diseases (Alt et al., 2012). C-35
bridges the chemical space between SB-612111 and the previ-
ously co-crystallized antagonist C-24, combining the dichloro-
phenyl head group of SB-612111 with the N-benzyl D-Pro tail
from C-24 (for chemical structures, see Table S2). During
in vitro assays, C-35 displayed high affinity (pKi = 9.14) and
selectivity (>300-fold) toward NOP over classical opioid recep-
tors (Trapella et al., 2009).
A summary of specific ligand-receptor interactions is pre-
sented in Figure 2. In both the SB-612111- and C-35-bound
structures, NOP adopts a very similar conformation as in
the previously determined NOP-C24 structure, with overall
root-mean-square deviations (RMSDs) of 0.37 A˚ (NOP-SB/
NOP-C24), and 0.45 A˚ (NOP-C35/NOP-C24) over receptor Ca
atoms (Figure 2A).
Antagonist SB-612111 (Figure 2B) is boundby a salt bridge be-
tween the protonated nitrogen of the piperidine and D1303.32
(superscripts following residues indicate Ballesteros-Weinstein99, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2293
Figure 2. Crystal Structures of Human NOP
Bound to Thermally Stabilizing Antagonists
(A) NOP co-crystal structure and (B–D) ligand-
binding modes reveal a highly conserved receptor
structure when bound to (B) SB-612111 (purple),
(C) Compound-35 (C-35; cyan), and (D) Banyu
Compound-24 (C-24; green). All three piperidine-
based antagonists participate in a salt-bridge
interaction with D1303.32, which anchors them to
the base of the orthosteric binding pocket. Ligands
and residues around the binding site are repre-
sented as sticks with non-carbon atoms colored
by atom type (chlorine, green; oxygen, red;
nitrogen, blue). Hydrogen bonds are represented
as yellow dashed lines. Superscripts indicate
the Ballesteros-Weinstein numbering convention
(Ballesteros and Weinstein, 1995). See also
Figure S3.numbering throughout the text; Ballesteros andWeinstein, 1995)
in a mode that resembles that of C-24 (Thompson et al., 2012).
The dichlorophenyl head group of SB-612111 is buried deep
within the hydrophobic sub-pocket outlined by residues
M1343.36, F1353.37, I2195.42, and V2836.55, while its relatively
short heterocyclic tail lies flat against Q1072.60 at the base of
thepocket but doesnotmakedirect polar interactionswith the re-
ceptor. A region of strong electron density in the pocketwithin the
transmembrane core of NOP-SB-612111 is flanked by residues
D972.50, N1333.35, S1373.39, and N3117.45 (Figure S3). This den-
sity is consistent with that of the sodium ion and water cluster
identified in the closely related d-opioid receptor and several
other classAGPCRs (Katritch et al., 2014), although ahigher-res-
olution structure is required to unambiguously resolve sodium
coordination in NOP.
The binding pose of C-35 (Figure 2C) is similar overall to that of
SB-612111, with its piperidine nitrogen forming a salt-bridge
interaction with D1303.32 and a hydrogen bond between its
amide nitrogen and Q1072.60. The dichlorophenyl head group
of C-35 is shifted slightly (0.8 A˚) from that of SB-612111 within
the hydrophobic sub-pocket.
All three co-crystallized ligands (SB-612111, C-35, and C-24)
contain a piperidine group whose protonated nitrogen partici-
pates in a salt-bridge interaction with D1303.32. Piperidine is a2294 Structure 23, 2291–2299, December 1, 2015 ª2015 Elsevier Ltd All rights reservedubiquitous building block in NOP ligand
design (Mustazza and Bastanzio, 2011),
and the piperidine-D1303.32 salt bridge
common to these structures offers a
direct rationalization for the high affinities
of this ligand class.
Although the D1303.32 residue is con-
served in all four opioid receptors, it plays
a crucial role in binding of the highly selec-
tive endogenous agonist N/OFQ (Moule-
dous et al., 2000; Thompson et al., 2012).
Because of this, interactions between
D1303.32 and ligands likely contribute to af-
finity rather than efficacy or selectivity.
Notably, the head groupof the antagonists
described here (a spiroisobenzofuran inC-24 and a dichlorophenyl in C-35 and SB-612111) lies perpen-
dicular to this piperidine ring in all cases, a structural feature pre-
viously suggested to be of importance to NOP ligand affinity and
efficacy (Trapella et al., 2009).
Docking Studies: Degenerate Ligand-Binding Modes
Correlate with Low Receptor Stability
To better understand the nature of stabilizing receptor interac-
tions with antagonists and potential conformational changes in
the receptor upon their binding, we performed molecular dock-
ing of several additional antagonists. We first validated our dock-
ing protocol by cross-docking the co-crystallized antagonists in
Figure 2 against all three NOP structures in the context of both
rigid and flexible receptor side chains. Cross-docking of antag-
onists C-35, SB-612111, and C-24 into all crystal structures of
NOP resulted in accurately reproduced binding poses with
RMSDs ranging from 0.6 to 1.3 A˚ (Table S3). Moreover, en-
ergy–based refinement of these compounds with extensive flex-
ible sampling of binding pocket side chains resulted in only very
minor variations in receptor and ligand conformations.
In contrast, docking of antagonist J-113397 and key deriva-
tives based on the compound’s 4-(2-keto-1-benzimidazolinyl)-
piperidine scaffold suggests substantial differences in the recep-
tor interactions with compounds of this chemotype (Kawamoto
Figure 3. Docking Studies Reveal Multiple Binding Modes for NOP
Antagonists and Offer Clues to Their Destabilizing Nature
Predicted binding modes of compounds (A) J-113397 (orange), (B) Trap-101
(violet), (C) Nor-BNI (yellow), and (D) UFP-101 (red) were docked into the NOP
model with flexible side chains and water sampling. For J-113397 and Trap-
101, two binding modes with comparable free energies were found (mode I:
left; ‘‘flipped’’ mode II: right). The locations of transmembrane helices 2 and 5
(H2, H5), along with the extracellular loop 2 (ECL2), are given. Water molecules
are represented by red (oxygen) and grey (hydrogen) spheres. Ligand chemical
structures are given in Table S2, explicit free energies of binding can be found
in Table S3, and detailed ligand-receptor interactions are shown in Figure S4.et al., 1999). Docking of J-113397 into the rigid NOP structure led
to an unexpected, flipped orientation (deemed mode II) of the
piperidine ring compared with co-crystallized ligands (Figure 3A,
right panel). Analysis of this bindingmode suggests that the ethyl
moiety on the benzimidazolinyl ring of J-113397 prevents it from
binding in the unflipped orientation (mode I) due to a severe steric
clash between the ethyl group and the Q2806.52 side chain. How-
ever, allowing conformational sampling of receptor side chains
and water during docking allowed J-113397 to bind in an orien-
tation similar to that of the co-crystallized ligands (mode I), with a
comparable free energy of binding (Figure 3A, left panel).
Similarly to J-113397, a flip between predicted rigid and flex-
ible receptor docking conformations was observed for Trap-101
(Figure 3B), an achiral analog of J-113397 with a double bond
introduced between C3 and C4 positions of the piperidine ring
(Trapella et al., 2006). Interestingly, the 3-hydroxymethyl moiety
of J-113397 and Trap-101 in mode I points deep into the pocket,
forming additional hydrogen bonds with both the D1303.32 side
chain and the adjacent water molecule observed in the crystal
structure (Figure S4). This tight binding of the 3-hydroxymethylStructure 23, 2291–22group is supported by previous structure-activity relationship
studies, which show that replacement of the 3-hydroxymethyl
with a bulkier COOCH3 moiety reduces binding of both
J-113397 and Trap-101 by about 100-fold (Trapella et al.,
2006). The residual binding of the Trap-101 3-COOCH3 deriva-
tive suggests that this chemotype can still bind in an alternative
conformation, likely similar to the flipped, mode II conformation
observed in rigid docking, albeit with greatly reduced affinity.
Multiple predicted binding modes were also observed for high-
affinity antagonist JTC-801, which adopted a distinct binding
mode buried in the crevice between helices 4 and 5 (Figure S4).
A Mechanism for Stabilization: Ligand-Receptor
Conformational Pairs
Analysis of the aforestated docking results (Figure 3) in the
context of thermostability data for these ligands (Figure 1) sug-
gests that the tight and unique binding poses of compounds
such as C-24, C-35, and SB-612111 may be one of the pre-
requisites for complex thermostabilization and conformational
stabilization that are critical for successful crystallogenesis.
Thus, compounds with at least two predicted alternative binding
poses, J-113397, Trap-101, and JTC-801, had reduced Tm
values and were not amenable for crystallization.
Interestingly, the peptide antagonist UFP-101 was not shown
to significantly stabilize NOP despite its exceptional sub-nano-
molar affinity (Figure 1D) (McDonald et al., 2003). Docking of
UFP-101 in our previous study (Thompson et al., 2012) showed
that its interactions with NOP were primarily electrostatic in na-
ture, with multiple positively charged residues in the C terminus
(residues 5–17) of UFP-101 binding to negatively charged recep-
tor side chains at the entrance of the binding pocket. Such inter-
actions are likely to be non-specific, with the numerous rotatable
bonds of UFP-101 allowing alternative salt-bridge pairings of
positively and negatively charged side chains, which further cor-
roborates the potential link between the multiplicity of ligand-
binding conformations and reduced thermostability.
Future Outlook: Ligand-Receptor Interactions and
Crystallization
Understanding GPCR signal transduction begins with detailed
knowledge of ligand-receptor interactions. Toward this aim,
identification of ligands that facilitate crystallogenesis for
GPCR structural studies is a major bottleneck, and has been
limited by our lack of understanding surrounding receptor stabi-
lization and its connection to crystallogenesis.
High receptor thermal stability (Tm) has become a hallmark of
pre-crystallization trials for GPCRs, as ligands that stabilize the
receptors are thought to aid in folding and increase the dwell
time of the receptor in the desired conformational state. The
linear relationship between ligand-induced Tm and antagonist
potency (pKB) provides us with another potential avenue by
which candidate ligands for crystallization may be identified. Un-
like Tm measurements, pKB values derived from BRET assays
can be measured using crude membrane preparations and, in
the case of b-arrestin variations on the assay, whole cells,
such that protein purification is no longer required. Due to the
ease of sample preparation, the BRET assay is more amenable
to adaptation as a high-throughput tool for ligand screening pur-
poses specifically for GPCR structural studies.99, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2295
Figure 4. Potential Mechanism for Ligand-Induced Receptor Stabil-
ity
(A) High-Tm ligands such as SB-612111 (purple) have a single permissible
docking orientation which promotes a uniform local conformation, high re-
ceptor stability, and isolation via crystallization.
(B) Low-Tm ligands such as J-113397 (orange/yellow) have two or more
bindingmodes with degenerate free energies, dividing the receptor population
between those bound to the ligand in mode I or II, and decreasing the likeli-
hood of isolating one receptor-ligand conformational pair via crystallization.Intensifying efforts to determine the relationship between
conformational heterogeneity and receptor stability have re-
sulted in a wealth of hypotheses surrounding the mechanism
of GPCR activation, as well as the influence of ligands on these
processes (Bock et al., 2014; Liu et al., 2012;Manglik et al., 2015;
Nygaard et al., 2013; Vaidehi et al., 2014). In the present study,
we determined the crystal structures of NOP in complex with an-
tagonists SB-612111 and C-35, extending the findings of the
previously reported antagonist-bound structure of NOP bound
to C-24. We also demonstrate a strong correlation between
antagonist pKB and thermostability, thus highlighting a high-
throughput strategy for identifying GPCR ligands for crystalliza-
tion. The increase in thermostability is consistent with a
reduction in receptor flexibility by shifting the conformational
equilibrium exclusively to the antagonized state. Docking studies
indicate that these potent antagonists, such as SB-612111, have
a single permissible binding mode that promotes a uniform local
conformation, high receptor stability, and isolation via crystalli-
zation (Figure 4A). In contrast, ligands that adoptmultiple binding
poses (such as J-113397, Trap-101, JTC-801, and UFP-101)
divide the receptor population by the number of binding orienta-
tions (Figure 4B); the resulting conformational heterogeneity de-
creases receptor stability as well as the probability of isolating
one receptor-ligand conformational pair via crystallization.
Because GPCRs maintain a dynamic equilibrium between
several conformational states corresponding to various signaling
events (Audet and Bouvier, 2012; Liu et al., 2012), an analogous
link between the degeneracy of receptor-ligand conformational
pairs and crystallization could potentially be extended to
active-state receptors. While the multiplicity of ligand-binding
modes stunts crystallization of inactive-state (antagonist-bound)2296 Structure 23, 2291–2299, December 1, 2015 ª2015 Elsevier Ltdreceptors, this degeneracy is further amplified in the presence
of agonists by virtue of multiple active-state conformations
(Manglik et al., 2015). Thus, selecting an agonist with a single
preferred binding orientation and strong conformational selec-
tivity towards one specific receptor substate over others may
boost receptor conformational homogeneity and the likelihood
of crystallogenesis.
Together, our results not only suggest a potential mechanism
for antagonist-induced receptor stabilization, but also point to
new avenues for identifying receptor-ligand pairs that are most
amenable to structural studies. Such advances in our under-
standing of ligand-receptor interactions will aid in the goal of un-
derstanding GPCR structural biology.
EXPERIMENTAL PROCEDURES
Chemical Compounds
The N/OFQ peptide was synthesized in-house following the procedures previ-
ously described in detail (Guerrini et al., 1997). The non-peptide molecules
C-35, C-24, Trap-101, and J-113397 were synthesized in-house by C.T. SB-
612111 was from Tocris Bioscience. All tissue culture media and supplements
were from Invitrogen. Reagents used were from Sigma Chemical or Merck,
and were of the highest purity available. Native coelenterazine (CLZN, 5 mM,
EtOH) was from Synchem UG. N/OFQ was dissolved in ultrapure water
(1 mM) while other ligands were dissolved in DMSO (10 mM) and kept at
20C until use.
Cell and Membrane Preparation for BRET Assay
Human embryonic kidney (HEK293) cells were grown in DMEM supplemented
with 10% (v/v) fetal calf serum, 100 units/ml penicillin G, and 100 ng/ml strep-
tomycin sulfate, in a humidified atmosphere of 5% CO2 at 37
C. Cell lines
permanently co-expressing NOP-RLuc and Gb1-RGFP were prepared using
the pantropic retroviral expression system by Clontech as described previ-
ously (Malfacini et al., 2015; Molinari et al., 2008).
NOP/G-protein interaction experiments were performed in enriched plasma
membrane aliquots from transfected cells prepared by differential centrifuga-
tion. In brief, cells were detached with 1 mM PBS/EDTA solution (pH 7.4
adjusted with NaOH) then, after 5min of centrifugation at 5003 g, Dounce-ho-
mogenized (30 strokes) in cold homogenization buffer (5 mM Tris, 1 mMEGTA,
1mMDTT [pH 7.4 adjusted with HCl]) in the presence of 0.32M sucrose. Three
following centrifugations were performed at 1,000 3 g (4C) and the superna-
tants kept. Two subsequent centrifugations at 25,0003 g (4C) (the second in
the absence of sucrose) were performed to separate enriched membranes
which, after discarding the supernatant, were kept in ultrapure water at
80C (Vachon et al., 1987). The protein concentration in membranes was
determined using the QPRO-BCA kit (Cyanagen) and a Beckman DU 520
spectrophotometer.
BRET Assays
Membrane bioluminescence was recorded in 96-well untreated white opaque
microplates (PerkinElmer). For the determination of NOP/G-protein interac-
tion, membranes (3 mg of protein) prepared as described above were added
to wells in Dulbecco’s PBS. NOP/G-protein interactions were measured in
the presence of CLZN (5 mM, injected 10 min prior to reading the cell plate)
in cell membranes; the contribution of other cellular processes (i.e., arrestin
recruitment, internalization) was hence negligible. Increasing concentrations
of N/OFQ were added in 20 ml of 0.01% PBS-BSA (BSA; Sigma Chemical)
15 min before reading luminescence. Luminescence signals were measured
as counts per second with a Victor X 2030 luminometer (PerkinElmer). Emis-
sions were selected using 460 nm (25 nm bandwidth) and 510 nm (10 nm
bandwidth) band-pass filters for Rluc and RGFP, respectively. All BRET exper-
iments were performed at room temperature.
BRET Assay Data Analysis
Concentration-response curves to N/OFQwere carried out in the absence and
presence of a fixed concentration of each antagonist. Antagonists were addedAll rights reserved
to membranes 15 min prior the addition of concentration-response curves to
N/OFQ. Following agonist injection, re-equilibration was allowed by leaving
agonist/antagonist to compete for 15 min before the measurement of BRET
ratio. All data were computed as stimulated BRET ratio units, i.e., the ratio be-
tween counts per second from RGFP and RLuc in the presence of ligands, fol-
lowed by baseline subtraction, i.e., the BRET value in the absence of ligand.
Maximal agonist effects (Emax) were expressed as a fraction of the N/OFQ
Emax, which was determined in every assay plate and reported as E/Emax,
in the graphs in Figure S2. Concentration-response curves to agonists and
inhibition response curves to antagonists were analyzed with a four-parameter
logistic non-linear regression model. Agonist data are expressed as mean ±
SEM of n experiments.
Antagonist potencies were derived with the equation pKB =
ðlogðCR 1ÞÞ  log½½B, where CR is the ratio between agonist potency (ex-
pressed as EC50) in the presence and absence of antagonist, and [B] is the
molar concentration of antagonist. Antagonist pKB values were derived from
at least four experiments performed in duplicate and are reported as mean ±
CL95%. The value pKB is the negative logarithm of the equilibrium dissociation
constant of an antagonist-receptor complex as determined through a func-
tional assay in which a physiological response is antagonized. In other words,
KB is the concentration of antagonist that occupies half of the receptor popu-
lation at equilibrium, expressed in units M. Curve fitting was performed using
PRISM 5.0 (GraphPad Software).
Protein Expression and Purification for Crystallogenesis
The human NOP receptor structures presented here use a previously
described fusion-partner construct and expression scheme (Thompson
et al., 2012). Details of receptor expression and purification are available in
the Supplemental Experimental Procedures. Receptor purity andmonodisper-
sity were monitored via SDS-PAGE and analytic size-exclusion chromatog-
raphy throughout purification. Typically, protein from 5 l of Spodoptera
frugiperda (Sf9) insect cell biomass was concentrated to 20 ml to yield a
concentrated solution of 40 mg/ml appropriate for one round of crystallization.
Lipidic Cubic Phase Crystallization
Concentrated protein samples were reconstituted into the LCP by mixing with
molten lipid using a mechanical syringe mixer at room temperature (20C–
22C) (Caffrey and Cherezov, 2009). The LCP mixture contained 40% (w/w)
concentrated protein, 54% (w/w) monoolein (Sigma), and 6% (w/w) choles-
terol (Avanti Polar Lipids). Crystallization trials were performed in 96-well glass
sandwich plates (Marienfeld) (Cherezov et al., 2004) onto which 40 nl of pro-
tein-containing LCP drops and 0.8 ml of precipitant solution were deposited
by the NT8-LCP (Formulatrix) or mosquito LCP (TTP Labtech) crystallization
robots. The crystallization plates were then sealed with a glass coverslip and
stored at 20C in an incubator/imager (RockImager 1000, Formulatrix). Diffrac-
tion quality crystals were grown and harvested after about 20 days in 25%–
35% (v/v) polyethylene glycol 400, 130–200 mM potassium sodium tartrate
tetrahydrate, and 100 mM Bis-Tris propane (pH 6.4). Crystals were collected
directly from LCP using 50 mm MiTeGen micromounts and immediately flash-
frozen in liquid nitrogen.
X-Ray Data Collection and Processing
X-Ray data were collected at the 23ID-B/D beamline (GM/CA-CAT) at the
Advanced Photon Source, Argonne National Laboratory, using a 10-mm colli-
mated minibeam with X-ray wavelength of 1.0330 A˚ and a MarMosaic 300
CCD detector. Due to radiation damage, typically 10–20 wedges of data
were collected from each crystal at 100 K using an unattenuated beam, with
1 of oscillation and 1–2 s of exposure, before changing the crystal.
Structure Determination and Refinement
Initial phases were obtained by molecular replacement with Phaser-MR
(McCoy, 2007) maximum-likelihood molecular replacement using the original
NOP-C24 structure as a search model (PDB: 4EA3, ligands removed, BRIL
and transmembrane domains searched for separately). Each asymmetric
unit contains two antiparallel receptors and one BRIL fusion partner. The sec-
ond BRIL fusion was not observed in any of the reported NOP structures, likely
due to disorder. Model building was performed with Coot (Emsley et al., 2010),
while structural refinement was carried out with PHENIX (Adams et al., 2010).Structure 23, 2291–22Crystallographic Rwork, as well as Rfree for 5% of the reflections excluded from
the refinement, were calculated to monitor the structural refinement proce-
dures. The results of the structural analysis are summarized in Table 1. Struc-
tural validation was performed using MolProbity (Chen et al., 2010). All molec-
ular graphics were produced with PyMOL molecular graphics system v.1.4.1
(Schroedinger).
Docking Assessment of Crystal Structures
Both rigid and flexible docking of small-molecule ligands into the available
crystal structures of NOP were performed using Internal Coordinate Me-
chanics (ICM) molecular modeling suite (Tables S2 and S3; Figure S4)
(Abagyan et al., 1994, 2009). For the rigid receptor docking, receptor
models were prepared from crystal structures by assigning and optimizing
conformations of hydrogen atoms and generating the set of grid potential
maps of the receptor in a 30 3 30 3 30-A˚ box covering the extracellular
half of the receptor. Ligand docking is based on biased probability Monte
Carlo optimization of the ligand internal coordinates (Totrov and Abagyan,
1997). Compounds in 2D representation were converted to 3D and energy
optimized using the MMFF-94 force field (Halgren, 1995); at least ten
random orientations of the ligand were used as starting conformations.
Monte Carlo sampling and optimization were performed at high thorough-
ness = 30. The objective energy function included the ligand internal strain
and a weighted sum of the grid map values in ligand atom centers. For the
flexible receptor docking, we used an explicit all-atom representation of the
receptor, where side chains within 6 A˚ of the ligand were considered flex-
ible. Extensive sampling of the ligand and side-chain conformations in the
binding pocket was performed using ICM global energy optimization (Totrov
and Abagyan, 1997).
To ensure convergence of the Monte Carlo optimization, five independent
runs of the docking procedure were performed, and the resulting poses
compared. The docking results of individual docking runs for each compound
were considered consistent if at least three of the docking runs produced
similar ligand conformations with RMSD < 2.0 A˚ and binding score <
14.0 kJ/mol. The ICM ligand-binding score (Bursulaya et al., 2003; Schapira
et al., 1999) was calculated as:
Sbind = Eint + TDSTor + Evw + a1 3 Eel + a2 3 Ehb + a3 3 Ehp + a4 3 Esf,
where Evw, Eel, Ehb, Ehp, and Esf are van der Waals, electrostatic, hydrogen
bonding, non-polar, and polar atom solvation energy differences between
bound and unbound states, Eint is the ligand internal strain, DSTor is its confor-
mational entropy loss upon binding, T = 300 K, and ai are ligand- and receptor-
independent constants. No distance restraints or any other experimentally
derived information was used in the ligand docking procedure.
ACCESSION NUMBERS
Coordinates and structure factors for the two crystal structures have been
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